Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
about
High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphomaPositron emission tomography (PET)-adapted therapy for Hodgkin lymphoma patientsHigh-dose chemotherapy followed by autologous stem cell transplantation for refractory/relapsed Hodgkin lymphoma patientsPrognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysisClinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated ReviewAdvancement in high dose therapy and autologous stem cell rescue in lymphomaThe role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphomaRole of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implicationsClassical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplantPembrolizumab in classical Hodgkin's lymphomaA randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantationPediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Randomized trials of high-dose chemotherapy in breast cancer: fraud, the press and the data (or lessons learned in medical policy governing clinical research).Hodgkin lymphoma, version 2.2015.Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas.Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment.Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignanciesEmerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.High-dose therapy for Hodgkin's disease.Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesAutologous stem cell transplantation for malignancy: a systematic review of the literature.Evidence-based management of Hodgkin's disease: the role of autologous stem cell transplantation.Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphomaDifferent response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma.The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Secondary leukaemia and myelodysplasia after autografting for lymphoma: is the transplant to blame?Hodgkin's lymphoma therapy: past, present, and future.Tandem transplantation in lymphoma.ChlVPP chemotherapy in children with stage IV Hodgkin's disease: results of the UKCCSG HD 8201 and HD 9201 studies.An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
P2860
Q24201885-142B925A-9A44-46A8-BCE5-6CF3DE54C829Q24202622-F546EC9B-CCE2-490B-BF8D-12638A78E622Q24235563-B2AAABAC-741C-4A9E-9D25-5B89FF326735Q26765151-1A4FEAEB-1D4A-4133-B256-13C501E565B8Q26770716-630E33CC-8377-499B-8705-4972727D484BQ26795538-CC760488-1BAC-4CC4-AEFD-A5DF94DF142EQ26822480-6B657EA4-A44E-46E1-9DFD-D15EDE144109Q27011510-595044BF-702A-4F3C-85AF-3F6C764F6ED2Q27022992-ECD8E614-58A9-48A8-A486-ADA226B9474BQ28079273-3DC23458-E2BB-4E8E-841D-B64DCB2BDF23Q28346786-32BA55BF-9086-499E-9417-A38E5B9C7049Q30248284-6EDA42A1-44C3-47CC-A90D-9996DF2E1972Q30696719-28C549A0-451A-489C-AB57-A43955D239E5Q30769157-5E2BAEA1-E709-4EFB-ADAA-1529B0AA3082Q33344684-0C687164-B11E-4950-9793-B0C7107820C8Q33347071-CA31566F-248B-46C8-9C7B-13873773CE60Q33349419-567BA088-0F58-48A6-B3D0-A94FCFD19E4EQ33365711-6AB0F442-5360-4595-B097-60F2F249F657Q33379431-C161BE42-BED3-4852-933E-AE6C5FA5D51EQ33389387-A18AA1CB-611D-4B91-9A70-D5547A9FF3ADQ33405891-83CB5858-F6D4-4199-B8EC-6478F2FAF173Q33406827-D1959296-0857-4672-8683-D50EBB95043EQ33411127-0E9D3403-0BB9-4C33-A74E-B7B937A86045Q33566475-7AA1637A-67DF-42CB-AACE-460CFFF829ECQ33704061-6A8919B9-FC84-4B83-A5F1-5E54D1352D08Q33801189-CB28B791-BFC2-4F9F-A140-A7FD9D3CB94DQ33828956-749DC33B-EF5A-4536-856D-39DAB8414DA3Q33886267-D6AA3C49-4498-4960-8124-C585041DD88DQ33904435-C3EB64F1-5CB9-4357-BABA-E81981C9CB82Q33930383-B99396E9-39F0-4D65-9063-720EB4141D94Q34064220-8959D1C8-65E9-4AD7-ACD0-6721FA3133A5Q34095620-025885E2-0505-4FA6-B59D-1DDDE8649DFAQ34240314-FFF15434-92F0-4F15-9D33-BBB989E29647Q34244398-F4FDF0DF-D7B0-4C63-B98F-061B94FD9048Q34296914-ECEBE6F0-F674-404B-9F6E-7188387BB8F3Q34405402-69CDB2F7-CB67-4C30-975D-8BB4ADF4D34CQ34529115-FDA1147B-2FA8-493D-BE4B-65D948360C2AQ34532766-914052C1-ACA4-4929-9EE3-D07C7CCDC870Q34545371-7C556A95-2174-4CBC-85AA-4C2BC24F9D96Q34570769-20B342B1-8E7E-4E58-BCA2-21A16CF6D742
P2860
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
description
1993 nî lūn-bûn
@nan
1993 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Dose intensification with auto ...... ts of a BNLI randomised trial.
@ast
Dose intensification with auto ...... ts of a BNLI randomised trial.
@en
Dose intensification with auto ...... ts of a BNLI randomised trial.
@nl
type
label
Dose intensification with auto ...... ts of a BNLI randomised trial.
@ast
Dose intensification with auto ...... ts of a BNLI randomised trial.
@en
Dose intensification with auto ...... ts of a BNLI randomised trial.
@nl
prefLabel
Dose intensification with auto ...... ts of a BNLI randomised trial.
@ast
Dose intensification with auto ...... ts of a BNLI randomised trial.
@en
Dose intensification with auto ...... ts of a BNLI randomised trial.
@nl
P2093
P1433
P1476
Dose intensification with auto ...... ts of a BNLI randomised trial.
@en
P2093
A H Goldstone
A McMillan
D Milligan
D Winfield
G V Hudson
P304
P356
10.1016/0140-6736(93)92411-L
P407
P577
1993-04-01T00:00:00Z